Article thumbnail

Prevention of diabetes in hypertensive patients: Results and implications from the VALUE trial

By Ming-Sheng Zhou and Ivonne Hernandez Schulman

Abstract

A growing number of experimental and clinical studies have provided evidence indicating that pharmacological blockade of the renin–angiotensin system (RAS) by either angiotensin-converting enzyme inhibitors or angiotensin type 1 receptor blockers reduces the incidence of new onset type 2 diabetes in subjects with hypertension and/or cardiovascular disease, independently of antihypertensive and cardiovascular protective effects. The beneficial effects of RAS inhibition on the development of diabetes have been largely attributed to improvements in peripheral insulin sensitivity and glucose metabolism. This review focuses on recent experimental and clinical evidence supporting the role of RAS inhibition in the reduction of new onset type 2 diabetes and the mechanisms that may be involved

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2686254
Provided by: PubMed Central

Suggested articles

Citations

  1. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly.
  2. (2007). A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.
  3. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression.
  4. Adverse prognostic significance of new diabetes in treated hypertensive subjects.
  5. Angiotensin blockade prevents type 2 diabetes by formation of fat cells.
  6. (2004). Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor
  7. (1997). Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels – A potential role for serine phosphorylation in insulin/angiotensin II crosstalk.
  8. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.
  9. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells.
  10. (2008). Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab.
  11. (2008). Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int.
  12. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
  13. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.
  14. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension.
  15. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. Diab Vasc Dis Res.
  16. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
  17. (2008). Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes. Diabetes Obes Metab.
  18. (2005). Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 rat.
  19. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
  20. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
  21. Effect of ramipril on the incidence of diabetes.
  22. (2006). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet.
  23. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
  24. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
  25. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
  26. (1998). Epidemiology of glucose intolerance and gestational diabetes in women of childbearing age. Diabetes Care.
  27. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA)
  28. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.
  29. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population.
  30. (2007). Improvement of insulin sensitivity by antagonism of the renin-angiotensin system.
  31. (2004). Insulin resistance and hypertension.
  32. (1994). Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release.
  33. Intracellular partition of plasma glucose disposal in hypertensive and normotensive subjects with type 2 diabetes mellitus.
  34. (2005). Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med.
  35. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
  36. Mechanisms linking obesity with cardiovascular disease.
  37. (2005). Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arteriosclers Thromb Vasc Biol.
  38. New-onset diabetes and antihypertensive drugs.
  39. New-onset diabetes, antihypertensive treatment, and outcome.
  40. Obesity induces a phenotypic switch in adipose tissue macrophage polarization.
  41. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
  42. (1996). Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am
  43. Physiology and pathophysiology of the adipose tissue renin-angiotensin system.
  44. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.
  45. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.
  46. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure.
  47. (2004). Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab.
  48. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes.
  49. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.
  50. (2008). Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol.
  51. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension.
  52. (2006). The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines? Am J Cardiovasc Drugs.
  53. (2005). The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care.
  54. The metabolic syndrome – a new worldwide definition.
  55. (2006). The metabolic syndrome: role of skeletal muscle metabolism. Ann Med.
  56. (1989). The natural history of type II diabetes. Practical Diabetes.
  57. The physiology of a local renin-angiotensin system in the pancreas.
  58. (2009). The role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension. Am J Physiol Heart Circ Physiol.
  59. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
  60. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004.
  61. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner.
  62. Tyr(612) and Tyr(632) in human insulin receptor substrate-1 are important for full activation of insulinstimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells.
  63. UCP2 is highly expressed in pancreatic alpha-cells and influences secretion and survival.
  64. (2009). Vascular insulin resistance: A potential link between cardiovascular and metabolic diseases. Curr Hypertens Rep.
  65. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.